The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Adaluzis 500mg Powder for concentrate for solution for infusion

500 milligram(s) Pdr/Conc/Soln for Infus

CorrevioPA2319/001/001

Main Information

Trade NameAdaluzis 500mg Powder for concentrate for solution for infusion
Active SubstancesCEFTOBIPROLE MEDOCARIL SODIUM
Strength500 milligram(s)
Dosage FormPdr/Conc/Soln for Infus
Licence HolderCorrevio
Licence NumberPA2319/001/001

Group Information

ATC CodeJ01DI Other cephalosporins and penems
J01DI01 ceftobiprole medocaril

Status

Authorised/WithdrawnAuthorised
Licence Issued29/09/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back